A Study to Assess the Bioavailability of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Male Subjects

Inclusion criteria

• Healthy male subjects;
• Age：≥18 and ≤45 on the date signing informed consent
• Body mass index (BMI): 18-25 kg/m2 and the weight ≥50 kg；
• Subjects are able to understand the study procedures and methods, and willing to strictly comply with the protocol and give written informed consent.

Exclusion criteria

A subject will be excluded if the answer to any of the following criteria is "yes":：

• Clinically significant abnormalities in physical examination and laboratory test results or 12-lead ECG, etc. in screening;
• Clinically significant abnormalities in Chest X-ray or abdominal B-ultrasound examination
• Positive serology screen for Hepatitis B( HBsAg), Hepatitis C(HCV), HIV and USR unheated serum reagin test.
• Smoking more than 10 cigarettes a day, drugs or alcohol abuse within 6 months prior to screening
• Participation in any investigational drug or medical instrument study within 3months prior to screening, participation in 3 and more than 3 drug tests in a recent year;
• Serious infection, trauma and major surgery within 4weeks prior to screening;
• Blood donation of ≥400 mL or severe blood lose and the volume of blood loss ≥400 mL within 4 weeks prior to screening, receiving blood transfusion treatment within 8 weeks prior to screening ;
• Use of any prescription medicine or herbal remedy, over the counter medication or dietary supplements such as vitamin, calcium within 2 weeks prior to screening.
• Use of heparin, alginic sodium diester , mannose ester within 4 weeks prior to screening；
• Vegetarian or person with dietary restrictions
• Subjects able to father a child are unwilling to use highly effective physical form of birth control from the trial period until 3 months after the completion of study.
• With diseases which could impact on the absorption, distribution, metabolism and excretion (ADME) of study drugs or protocol adherence in the opinion of the investigator (such medical disorder/disease may relate to ccardiovascular, liver, kidney, digestive, immune, blood, endocrine, metabolic, cancer, neuropsychiatric,etc );
• Subjects may be allergic to GV-971 in the opinion of the investigator.
• Any other reasons that the subject is not eligible for participation in the study in the opinion of the investigator.